Duchenne Muscular Dystrophy (DMD)

Duchenne muscular dystrophy is a genetic disorder in which alterations of a protein called dystrophin lead to progressive muscle degeneration and weakness.

MDA logo
Blog Post

Mallinckrodt Pharmaceuticals Releases Statement to DMD Community Announcing Discontinuation of Clinical Trials Program for DMD

By MDA Staff | December 20, 2019
Blog Post

Santhera Pharmaceuticals Announces Publication of Positive Long-Term Results from Retrospective Study of Idebenone in DMD

By Jeanene Swanson | December 18, 2019
MDA logo
Blog Post

Solid Biosciences Releases Letter to DMD Community Announcing Update on IGNITE DMD Trial, Resolution of Serious Adverse Event

By MDA Staff | December 18, 2019
MDA logo
Blog Post

Wave Life Sciences Releases Letter to DMD Community Announcing Discontinuation of Clinical Trials Program for Therapies Amenable to Skipping Exons 51 and 53

By MDA Staff | December 16, 2019
Illustration of DNA
Blog Post

FDA Approves Sarepta Therapeutics’ Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | December 13, 2019
MDA logo
Blog Post

Santhera Pharmaceuticals Releases Letter to DMD Community Announcing Temporary Suspension of Enrollment in BreatheDMD Expanded Access Program

By MDA Staff | November 26, 2019
MDA logo
Blog Post

Solid Biosciences Releases Letter to DMD Community Announcing Hold on IGNITE DMD Trial Due to a Serious Adverse Event

By MDA Staff | November 12, 2019
Blog Post

Roche Genentech Releases Letter to DMD Community Announcing Discontinuation of Clinical Trials Program for DMD

By MDA Staff | November 6, 2019
Blog Post

World Muscle Society Roundup: Clinical Trial Results of Treatments in Development for DMD, XLMTM, SMA, and Pompe Disease

By Jeanene Swanson | October 31, 2019
Blog Post

Capricor Therapeutics Announces Positive Interim Results from Phase 2 Study of CAP-1002 to Treat DMD

By Jeanene Swanson | October 29, 2019